XML 27 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Related Party Transactions
3 Months Ended
Mar. 31, 2012
RELATED PARTY TRANSACTION [Abstract]  
Related Party Transactions Disclosure [Text Block]
RELATED PARTY TRANSACTIONS
The table below presents the transactions between the Company and Watson.
 
Three Months Ended
March 31,
 
 
2012
 
2011
 
REVENUES
 

 
 

 
Net product revenues
$
240,401

 
$
426,780

 
Royalties
600,000

 
540,000

 
Amortization of deferred revenue

 
8,393,926

 
Total net revenues
$
840,401

 
$
9,360,706

 
 
 
 
 
 
COST OF PRODUCT REVENUES
 

 
 

 
Cost of product revenues
218,546

 
388,133

 
Gross profit
$
621,855

 
$
8,972,573

 
 
 
 
 
 
 
 
 
 
 
Accounts receivable
$
1,256,203

 
$
555,441

 

The Company has exceeded the cap of $7.0 million by $3.6 million for R&D spending on the PREGNANT study and related Preterm Birth NDA pursuant to the Watson Transactions and has recorded this amount as a reduction of R&D expenses. Watson has paid the Company for $3.2 million of these excess amounts and has been invoiced for the remaining $0.4 million equal to the R&D expense reimbursement recognized in the first quarter of 2012.